MARKET

ATNM

ATNM

Actinium Pharmac
AMEX
7.45
+0.07
+0.95%
After Hours: 7.34 -0.11 -1.48% 18:45 07/12 EDT
OPEN
7.47
PREV CLOSE
7.38
HIGH
7.78
LOW
7.33
VOLUME
305.77K
TURNOVER
0
52 WEEK HIGH
10.24
52 WEEK LOW
4.000
MARKET CAP
221.89M
P/E (TTM)
-4.3304
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATNM last week (0701-0705)?
Weekly Report · 6d ago
Actinium Pharmaceuticals: Oversold Despite No Bad News
Actinium Pharmaceuticals, Inc. Is a biotech company focused on developing radiolabeled biologics for blood cancer treatment. Positive late-stage data supports Iomab-B approval for relapsed/refractory AML patients. The company has a strong cash position and a potential approval for the treatment by 2025. Uncertainty around approval timelines and lack of BLA submission has led to a decrease in valuation.
Seeking Alpha · 07/05 18:35
Weekly Report: what happened at ATNM last week (0624-0628)?
Weekly Report · 07/01 09:47
Weekly Report: what happened at ATNM last week (0617-0621)?
Weekly Report · 06/24 09:50
Buy Rating Reiterated for Actinium Pharmaceuticals Amid Promising AML Therapy Developments
TipRanks · 06/18 13:35
Actinium Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 06/17 14:55
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Benzinga · 06/17 14:45
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Syndax Pharmaceuticals (SNDX)
TipRanks · 06/17 14:40
More
About ATNM
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Webull offers Actinium Pharmaceuticals Inc stock information, including AMEX: ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.